General Information of Disease (ID: DISL8MX9)

Disease Name Attention deficit hyperactivity disorder
Synonyms ADHD; attention deficit/hyperactivity disorder; attention deficit hyperactivity disorder; attention deficit-hyperactivity disorder
Disease Class 6A05: Attention deficit hyperactivity disorder
Definition
A disorder characterized by a marked pattern of inattention and/or hyperactivity-impulsivity that is inconsistent with developmental level and clearly interferes with functioning in at least two settings (e.g. at home and at school). When present, the symptoms of hyperactivity are most often present before the age of 7 years. There are three recognized presentations or subtypes from most to least common: combined type, inattentive/distractible type, hyperactive/impulsive type.
Disease Hierarchy
DISLR2HH: Specific developmental disorder
DISL8MX9: Attention deficit hyperactivity disorder
ICD Code
ICD-11
ICD-11: 6A05.Z
ICD-9
ICD-9: 314
Expand ICD-11
'6A05
Expand ICD-10
'F90; 'F90.0; 'F90.8; 'F90.9
Expand ICD-9
314
Disease Identifiers
MONDO ID
MONDO_0007743
MESH ID
D001289
UMLS CUI
C1263846
OMIM ID
143465
MedGen ID
220387
HPO ID
HP:0007018
SNOMED CT ID
406506008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 17 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Altropane DMO9WDS Approved Small molecular drug [1]
Amphetamine DMSZQAK Approved Small molecular drug [2]
Atomoxetine DM5L6HI Approved Small molecular drug [3]
Clonidine DM6RZ9Q Approved Small molecular drug [4]
Connexyn DMF29Q5 Approved Small molecular drug [5]
Dasotraline DMLDQFV Approved Small molecular drug [6]
Desipramine DMT2FDC Approved Small molecular drug [7]
Dexmethylphenidate DMUQE2A Approved NA []
DEXMETHYLPHENIDATE HYDROCHLORIDE DM8WBAH Approved Small molecular drug [2]
Dextroamphetamine DMMIHVP Approved Small molecular drug [2]
Guanfacine extended release DMB1CZ8 Approved Small molecular drug [8]
Lisdexamfetamine DM6W8V5 Approved Small molecular drug [9]
Methamphetamine DMPM4SK Approved Small molecular drug [10]
Methylphenidate DM7SJD6 Approved Small molecular drug [11]
Pemoline DMSTTV9 Approved Small molecular drug [2]
Guanfacine DMPN5IH Phase 4 NA [12]
SPN-812 DMTV7XH Phase 4 Small molecular drug [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 Drug(s)
This Disease is Treated as An Indication in 36 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CM-AT DMLMN2F Phase 3 NA [14]
DOV-216419 DMKGEBB Phase 3 NA [15]
Eltoprazine DMW6C81 Phase 3 Small molecular drug [6]
HDL-200 DM0R2PO Phase 3 NA [16]
JNS-001 DMQB6HD Phase 3 NA [17]
KP415 DMRX7UZ Phase 3 NA [18]
KP484 DM7ZJ0U Phase 3 Small molecular drug [19]
NT0202 DMCMIJ1 Phase 3 NA [20]
NWP-09 DMHVW92 Phase 3 NA [21]
SPD-465 DM7NV1I Phase 3 NA [20]
SPN-810 DM0ILOX Phase 3 NA [6]
TRI-102 DMC8T1F Phase 3 NA [22]
YY-162 DMBQVBG Phase 3 NA [23]
AEVI-1 DMQNWXM Phase 2 NA [6]
Antistasin DMDKRS3 Phase 2 NA [24]
AR08 DM93CTQ Phase 2 NA [25]
Bavisant DM6CVZ5 Phase 2 Small molecular drug [26]
CX-1739 DMJD7H4 Phase 2 NA [27]
EB-1020 DMKGSWM Phase 2 NA [28]
HLD100 DMWLASA Phase 2 NA [6]
Mical DM04DRQ Phase 2 Small molecular drug [29]
NLS-001 DMFJAG7 Phase 2 NA [30]
NLS-1 DMTFR5B Phase 2 NA [6]
NS 2359 DMI5HFU Phase 2 Small molecular drug [31]
OPC-64005 DMIK2AD Phase 2 NA [32]
PDC-1421 DMGP9VN Phase 2 NA [33]
RP5063 DMKUE8O Phase 2 NA [6]
Sofinicline DM157U0 Phase 2 Small molecular drug [34]
HDL-100 DM0MQ2L Phase 1/2 NA [35]
ND-0801 DMCDQX0 Phase 1/2 NA [36]
CTX-1301 DMFGADW Phase 1 NA [6]
KRL-401 DMZ1CJL Phase 1 NA [37]
ORADUR-ADHD DMW2XH6 Phase 1 NA [38]
SKL13865 DM81JWE Phase 1 NA [6]
SPN-811 DMEBVET Phase 1 NA [39]
TRN-110 DMTO79N Clinical Trial NA [40]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 Drug(s)
This Disease is Treated as An Indication in 2 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID30124346-Compound-13TABLE4 DMHTJVA Patented Small molecular drug [41]
PMID30124346-Compound-34TABLE4 DM2G3VE Patented Small molecular drug [41]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 7 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ABT-089 DM8DT7U Discontinued in Phase 2 Small molecular drug [8]
Cipralisant DMTAKNF Discontinued in Phase 2 Small molecular drug [42]
R-sibutramine metabolite DMPAH74 Discontinued in Phase 2 NA [31]
ABT-107 DMPCYV6 Discontinued in Phase 1 Small molecular drug [43]
KP106 DMICLMR Discontinued in Phase 1 NA [44]
Fluoratec DM7JT3D Terminated NA [47]
SPPI-339 DM22NUJ Terminated NA [48]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Drug(s)
This Disease is Treated as An Indication in 3 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
HLD200 DM1U3XL Application submitted NA [6]
COL-171 DMFRG2B Preclinical NA [45]
EG-P119 DMMPKMU Preclinical NA [46]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
A-317920 DM124K5 Investigative Small molecular drug [49]
CM-4612 DM05CF2 Investigative NA [50]
CX-2007 DMCVCV5 Investigative NA [50]
CX-2076 DM8G276 Investigative NA [50]
PF-3409409 DMEZA0T Investigative Small molecular drug [51]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 116 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
DRD5 TTS2PH3 No Known Unknown [52]
ADORA2A TTM2AOE Limited Biomarker [53]
GJB2 TTRGZX3 Limited Biomarker [54]
GRM5 TTHS256 Limited Biomarker [55]
GRM8 TT0IFKL Limited Biomarker [55]
HTR1A TTSQIFT Limited Biomarker [56]
SDHD TTVH9W8 Limited Biomarker [57]
STS TTHM0R1 Limited Genetic Variation [58]
ADCY2 TTBQ9IM moderate Genetic Variation [59]
ADGRL3 TTQST3U moderate Biomarker [60]
CHRNB2 TT5KPZR moderate Biomarker [61]
CYP2D6 TTVG215 moderate Genetic Variation [62]
ELK3 TT5OJMV moderate Biomarker [63]
GRM1 TTVBPDM moderate Biomarker [64]
RXRG TTH029C moderate Genetic Variation [59]
THRA TTTSEPU moderate Biomarker [65]
ADRA1A TTNGILX Strong Genetic Variation [66]
ADRA1B TTBRKXS Strong Biomarker [67]
ADRA2B TTWM4TY Strong Genetic Variation [66]
ADRA2C TT2NUT5 Strong Genetic Variation [68]
BRCA2 TTUARD6 Strong CausalMutation [69]
BRS3 TTKYEPM Strong Genetic Variation [66]
BRSK2 TTHZN4X Strong Genetic Variation [70]
C9orf72 TTA4SHR Strong Biomarker [71]
CACNA1A TTX4QDJ Strong CausalMutation [72]
CACNA1C TTZIFHC Strong Biomarker [73]
CALY TT0R12H Strong Biomarker [74]
CES1 TTMF541 Strong Genetic Variation [75]
CFP TTLA0VS Strong Biomarker [76]
CHRNA4 TT4H1MQ Strong Biomarker [77]
CHRNA5 TTH2QRX Strong Genetic Variation [78]
CHRNA7 TTLA931 Strong Biomarker [79]
CHRNB4 TTTVAFQ Strong Genetic Variation [80]
CNR1 TT6OEDT Strong Biomarker [81]
CNTFR TTT2F9E Strong Genetic Variation [82]
CRY1 TT5MLZR Strong Altered Expression [83]
CXCR6 TT2BVUA Strong Genetic Variation [66]
DAPK3 TTERVQN Strong Biomarker [84]
DCLK1 TTOHTCY Strong Genetic Variation [85]
DDC TTN451K Strong Altered Expression [86]
DPP10 TTOVUPC Strong Biomarker [87]
DRD1 TTZFYLI Strong Altered Expression [88]
DRD3 TT4C8EA Strong Genetic Variation [89]
EPHA5 TTV9KOD Strong Genetic Variation [90]
EPHB1 TT8MDAC Strong Altered Expression [91]
GAD1 TTKGEP3 Strong Altered Expression [92]
GALR1 TTX3HNZ Strong Biomarker [93]
GRIA1 TTVPQTF Strong Biomarker [94]
GRIA2 TTWM461 Strong Biomarker [95]
GRIK5 TTO6LI7 Strong Biomarker [96]
GRIN2A TTKJEMQ Strong Genetic Variation [97]
GRIN2B TTN9D8E Strong Genetic Variation [98]
GRM7 TT0I76D Strong Genetic Variation [99]
GUCY2C TTLDPRG Strong Biomarker [100]
GUCY2D TTWNFC2 Strong Genetic Variation [101]
HCRT TTU5HJP Strong Altered Expression [102]
HRC TTR4FKD Strong Genetic Variation [103]
HRH3 TT9JNIC Strong Biomarker [104]
HTR1D TT6MSOK Strong Genetic Variation [105]
HTR1E TTCPG9S Strong Genetic Variation [56]
HTR2A TTJQOD7 Strong Genetic Variation [56]
HTR3A TTPC4TU Strong Biomarker [56]
HTR4 TT07C3Y Strong Genetic Variation [106]
HTR5A TTRUFDT Strong Biomarker [107]
HTR6 TTJS8PY Strong Genetic Variation [107]
ITGA1 TTPERWV Strong Genetic Variation [108]
ITGA11 TTANXZ7 Strong Genetic Variation [109]
ITGAE TTH0Z37 Strong Genetic Variation [109]
ITPR3 TTH1769 Strong Genetic Variation [110]
KCNC1 TTVUWHQ Strong Genetic Variation [111]
KCNH3 TTZ4MTQ Strong Biomarker [112]
KCNJ11 TT329V4 Strong Genetic Variation [113]
KCNJ5 TTEO25X Strong Biomarker [114]
KCNJ6 TTTIBVP Strong Genetic Variation [115]
LAIR1 TTSI7A8 Strong Biomarker [116]
LPAR2 TTB7Y8I Strong Genetic Variation [66]
MAOB TTGP7BY Strong Biomarker [117]
MC4R TTD0CIQ Strong Genetic Variation [118]
MECP2 TTTAU9R Strong Genetic Variation [119]
MFGE8 TT1GLAJ Strong Genetic Variation [120]
MOBP TTYUK4F Strong Genetic Variation [109]
MTNR1A TT0WAIE Strong Genetic Variation [121]
MTR TTUTO39 Strong Genetic Variation [122]
NCL TTK1V5Q Strong Genetic Variation [123]
NDUFAF2 TTCHGVF Strong Genetic Variation [124]
NISCH TT789FN Strong Biomarker [125]
NPY TT64REZ Strong Biomarker [102]
NR4A2 TT9HKN3 Strong Biomarker [126]
NSD1 TTTSJ3H Strong Genetic Variation [127]
NUAK1 TT65FL0 Strong Genetic Variation [128]
NUDT3 TT69I0C Strong Genetic Variation [129]
OXTR TTSCIUP Strong Biomarker [130]
PDE10A TTJW4LU Strong Genetic Variation [131]
PDE2A TTJGW1Z Strong Biomarker [132]
PKMYT1 TTB4PAZ Strong Biomarker [133]
SLC12A6 TT8DFHE Strong Genetic Variation [134]
SLC18A2 TTNZRI3 Strong Biomarker [135]
SLC1A3 TT8WRDA Strong Genetic Variation [136]
SLC5A4 TTN7Y4P Strong Genetic Variation [137]
SLC6A1 TTPRKM0 Strong Posttranslational Modification [138]
SLC6A9 TTHJTF7 Strong Genetic Variation [139]
SNAP25 TTYQWA0 Strong Biomarker [140]
SPN TTOZAX0 Strong Biomarker [141]
SSTR4 TTAE1BR Strong Genetic Variation [66]
TACR1 TTZPO1L Strong Biomarker [142]
TERF1 TT1Y6J2 Strong Biomarker [143]
TRH TT2Z39D Strong Biomarker [143]
VIPR2 TT4O5P0 Strong Biomarker [144]
DMD TTWLFXU Definitive Genetic Variation [145]
DRD2 TTEX248 Definitive Biomarker [53]
MOG TTQAFX5 Definitive Genetic Variation [146]
NTRK2 TTKN7QR Definitive Biomarker [82]
PAH TTGSVH2 Definitive Genetic Variation [147]
PRKG1 TT7IZSA Definitive Genetic Variation [148]
SLC6A8 TTYUHB5 Definitive Biomarker [149]
THRB TTGER3L Definitive Genetic Variation [150]
------------------------------------------------------------------------------------
⏷ Show the Full List of 116 DTT(s)
This Disease Is Related to 9 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC4A10 DT7RYVF moderate Genetic Variation [59]
CACNB2 DTBZWL4 Strong Genetic Variation [151]
CACNG2 DTRL7OG Strong Biomarker [152]
SLC2A3 DT9SQ3L Strong Genetic Variation [153]
SLC30A10 DTYBI73 Strong Genetic Variation [154]
SLC39A8 DTLPQGT Strong Genetic Variation [154]
SLC9A6 DTN0JXW Strong Biomarker [155]
SLC9A9 DT8LP62 Strong Biomarker [156]
SLC39A13 DTOTKBS Definitive Biomarker [157]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTP(s)
This Disease Is Related to 10 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
AS3MT DE9KJP3 Strong Biomarker [158]
ASMT DEHGR57 Strong Genetic Variation [121]
CYP4F3 DEFCMPI Strong Genetic Variation [159]
FAAH DEUM1EX Strong Genetic Variation [160]
KYAT1 DES9MCU Strong Biomarker [161]
MANBA DEMH6UB Strong Genetic Variation [110]
NT5C DE4E31Z Strong Biomarker [162]
NT5C2 DE1DOKJ Strong Genetic Variation [151]
SCLY DEH4TD6 Strong Genetic Variation [163]
TGM5 DEW8QEH Definitive Biomarker [157]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DME(s)
This Disease Is Related to 219 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
DRD5 OTYVGPOP No Known Unknown [52]
ARSD OTAHW9M8 Limited Biomarker [164]
ASH1L OTUT5NLJ Limited Genetic Variation [165]
CHPT1 OT4FJ0K3 Limited Biomarker [166]
CORO1A OTVAZOHC Limited Genetic Variation [167]
EDA OTAKS5WS Limited Biomarker [168]
FOXP2 OTVX6A59 Limited Genetic Variation [169]
INSRR OT3F75WA Limited Biomarker [170]
MTFMT OT1OIVJL Limited CausalMutation [171]
NDRG2 OT5L6KD7 Limited Biomarker [172]
PTCHD1 OTFDLU5S Limited Biomarker [173]
ST3GAL3 OTOORKUE Limited Genetic Variation [174]
SYP OTFJKMO4 Limited Biomarker [175]
ASCC2 OT3B204T moderate Genetic Variation [59]
CEP85L OTSHJFOT moderate Genetic Variation [59]
CLOCK OTNEOJY7 moderate Biomarker [176]
CNTN5 OTWU5FLZ moderate Biomarker [177]
CNTN6 OTXVGVOR moderate Biomarker [177]
FGD1 OTV3T64P moderate Genetic Variation [178]
MARK1 OTP7KL47 moderate Genetic Variation [179]
MED13 OTP5LEJE moderate Biomarker [180]
NLGN1 OTGHRRFQ moderate Genetic Variation [59]
PTPRD OTZPJ3GX moderate Biomarker [181]
RAB40B OTCA9ZF5 moderate Genetic Variation [182]
ACOXL OTW680HT Strong Genetic Variation [128]
ADAM12 OTZKOTDB Strong Genetic Variation [183]
AGA OTNWT1WB Strong Biomarker [184]
AGO1 OTD3R434 Strong Genetic Variation [185]
AK8 OT2UF6YM Strong Genetic Variation [109]
AMPD1 OTU17BCI Strong Biomarker [86]
AMPH OTWPGWZX Strong Biomarker [186]
ANK3 OTJ3IRBP Strong Genetic Variation [151]
ANKK1 OT0OM1O0 Strong Biomarker [87]
ATP2C2 OTGIHTYQ Strong Genetic Variation [109]
ATXN1 OTQF0HNR Strong Altered Expression [187]
ATXN7 OTL3YF1H Strong Biomarker [188]
B4GALT2 OTYIQT2F Strong Genetic Variation [189]
BAG3 OTVXYUDQ Strong Genetic Variation [190]
BAIAP2 OT1KKMYZ Strong Genetic Variation [191]
BCL2L10 OTYXQJ3I Strong Biomarker [192]
BHMT OTYB6PXZ Strong Genetic Variation [122]
BRINP1 OTEUVSCP Strong Altered Expression [193]
BTBD9 OTWQ6GA3 Strong Biomarker [194]
CARTPT OTTE4V9S Strong Biomarker [195]
CD79A OTOJC8DV Strong Biomarker [196]
CDH13 OTD2CYM5 Strong Genetic Variation [197]
CDKL5 OTGL5HRV Strong Biomarker [198]
CEP112 OT90U05G Strong Genetic Variation [199]
CFAP221 OTUVNCVZ Strong Genetic Variation [109]
CHRNA3 OTCZQY1U Strong Genetic Variation [80]
CHRNA6 OTT6W86V Strong Genetic Variation [200]
CHRNB3 OTE5XENW Strong Biomarker [200]
CIC OTFXCHNZ Strong Biomarker [201]
CLEC19A OTGRM6L0 Strong Biomarker [202]
CLTA OTLHOXMQ Strong Genetic Variation [101]
CNNM2 OTZHO8WU Strong Genetic Variation [151]
CNTNAP2 OT48T2ZP Strong Biomarker [203]
COA7 OTRQJYL6 Strong Biomarker [204]
CSMD1 OTIVDSC4 Strong Genetic Variation [151]
CSMD2 OT541Z3W Strong Genetic Variation [109]
CSRNP3 OTOANEHZ Strong Genetic Variation [174]
CYBC1 OTGTH90I Strong Biomarker [186]
DCD OTV5PBGJ Strong Biomarker [205]
DCDC2 OTSUFH1H Strong Biomarker [206]
DGKH OTYNPJ4B Strong Biomarker [207]
DHDDS OTVLYBUS Strong Biomarker [166]
DIRAS2 OT2DAIWW Strong Altered Expression [208]
DISC1 OT43AW4H Strong Altered Expression [86]
DLG2 OTQ3BD8U Strong Biomarker [132]
DLGAP1 OTF2PUUI Strong Biomarker [209]
DLX4 OTLWVCN4 Strong Biomarker [210]
DNAJC12 OTNU59PT Strong Biomarker [211]
DTNBP1 OT9UQT2S Strong Biomarker [212]
EBPL OT59J1GY Strong Biomarker [63]
ELFN1 OTM7M52U Strong Genetic Variation [213]
EMP2 OTPS2H0L Strong Genetic Variation [199]
FBXL16 OT3OTNLM Strong Genetic Variation [174]
FBXO33 OTENSSJD Strong Biomarker [214]
FERMT3 OTFQOT3C Strong Genetic Variation [215]
FEZ1 OTWCXPRE Strong Genetic Variation [151]
FEZF1 OTRX4NOT Strong Biomarker [216]
FLRT3 OT3XMZU3 Strong Genetic Variation [217]
FRRS1L OT24ABVC Strong Biomarker [218]
GFI1 OT9HB9H8 Strong Biomarker [219]
GIT1 OTHO92S5 Strong Biomarker [220]
GNPAT OTF6LWPO Strong Biomarker [221]
GPC6 OTNJBESF Strong Genetic Variation [109]
GPHN OTAKK1SV Strong Genetic Variation [222]
GPR42 OTEB0ROY Strong Genetic Variation [66]
GPR50 OT0EJBM4 Strong Biomarker [121]
GPRC5B OTF3S5E3 Strong Biomarker [129]
GYPA OTABU4YV Strong Biomarker [223]
HLA-DMB OT17HGXJ Strong Genetic Variation [151]
HTRA2 OTC7616F Strong Altered Expression [224]
IMPACT OTQ923OB Strong Biomarker [225]
IPO11 OTG19WN0 Strong Biomarker [226]
ITM2B OTMXEPXB Strong Biomarker [227]
ITPA OTQ47WVR Strong Biomarker [228]
KALRN OT8WRCBH Strong Biomarker [109]
KCNIP1 OTGLGK1R Strong Genetic Variation [111]
KCNIP4 OTB1BS0X Strong Biomarker [229]
KRT7 OTLT3JFN Strong Genetic Variation [163]
KYAT3 OTO4U2QK Strong Biomarker [161]
LAMB2 OT71OI2Y Strong Genetic Variation [230]
LGI1 OTPS77HO Strong Genetic Variation [231]
LIN7A OTFL3PUX Strong Biomarker [232]
LMAN2L OTJ9FAWS Strong Genetic Variation [233]
LMX1B OTM8145D Strong Biomarker [234]
LXN OTZQ2M6Y Strong Biomarker [235]
MAN2A2 OTQFECB6 Strong Genetic Variation [109]
MAP1B OTVXW089 Strong Genetic Variation [236]
MBOAT7 OTHRCBLK Strong Genetic Variation [237]
MEF2C OTZGF1Y5 Strong Genetic Variation [174]
MICALL2 OT1IQM3K Strong Biomarker [238]
MITF OT6XJCZH Strong CausalMutation [239]
MLIP OTMT7AII Strong Genetic Variation [174]
MNT OTPC4ANL Strong Biomarker [240]
MPP2 OTPH8CZY Strong Genetic Variation [132]
MTA2 OTCCYIQJ Strong Genetic Variation [241]
MUCL3 OTGAD3I0 Strong Genetic Variation [151]
MXD1 OTS5CTHX Strong Biomarker [86]
MYO5B OTCKL3W3 Strong Genetic Variation [242]
MYT1 OTC3660I Strong Biomarker [133]
NANS OTMQ2FUH Strong Biomarker [243]
NAT8L OTA96AVN Strong Biomarker [244]
NCAN OT8OO6ZE Strong Genetic Variation [233]
NET1 OTZHNMJV Strong Genetic Variation [245]
NPNT OTFZAO1G Strong Biomarker [246]
NRG3 OTIFZ5CT Strong Biomarker [247]
NRSN1 OT1KKXC8 Strong Biomarker [248]
NRXN1 OTJN1JQA Strong Genetic Variation [249]
NTM OTHF0UQU Strong Genetic Variation [183]
NTPCR OTTRT6Z9 Strong Biomarker [228]
NUFIP2 OTZBZ224 Strong Biomarker [250]
OTP OTS0JN6Y Strong Genetic Variation [251]
P4HTM OTKELL7F Strong Biomarker [252]
PADI1 OT13WAQX Strong Biomarker [253]
PDLIM1 OT4EGCPG Strong Biomarker [254]
PER2 OTU2B1DJ Strong Altered Expression [83]
PEX2 OTKOEYRM Strong Biomarker [255]
PFN1 OTHTGA1H Strong Biomarker [256]
PHLDA2 OTMV9DPP Strong Biomarker [257]
PI4K2B OT0D51QP Strong Genetic Variation [258]
PIDD1 OTWFM930 Strong Genetic Variation [259]
PIWIL4 OTDA9MY0 Strong Genetic Variation [260]
PLA1A OT2IXYNX Strong Genetic Variation [261]
PMCH OT3D9SA4 Strong Biomarker [262]
POLG OTDUCT04 Strong Genetic Variation [263]
POLR3A OT5MSK10 Strong Biomarker [264]
PRPF6 OT3U0ABN Strong Biomarker [265]
PRXL2C OTI8ZAK8 Strong Genetic Variation [266]
PSD OTUZIXUZ Strong Biomarker [267]
PSG5 OTHTU98X Strong Biomarker [268]
PSMD14 OTJWHMZ5 Strong Biomarker [253]
PTPRF OTH5KF2D Strong Genetic Variation [169]
PTPRG OT9N2WOF Strong Genetic Variation [59]
PTPRN2 OTL6SH28 Strong Genetic Variation [269]
RASGRP1 OTX9WN2E Strong Biomarker [132]
RBFOX1 OTFPKEL7 Strong Genetic Variation [270]
REM1 OTUXL0HC Strong Biomarker [271]
RERE OT3G4GBZ Strong Genetic Variation [151]
RFC1 OT3L5PK3 Strong Genetic Variation [122]
RNF122 OT8RE3IM Strong Biomarker [272]
RRS1 OTTNCZN6 Strong Biomarker [273]
SCAPER OT7S3B3P Strong CausalMutation [274]
SEC23IP OTTZ0FXP Strong Biomarker [267]
SEMA6D OTU0UAZS Strong Genetic Variation [270]
SERPINF2 OTZGAF8B Strong Genetic Variation [275]
SFTA2 OTVRIUIV Strong Genetic Variation [151]
SH2B2 OTEDHHDH Strong Biomarker [276]
SKI OT4KJ8F6 Strong Biomarker [255]
SMS OT8JYKNH Strong Biomarker [277]
SNORC OTY3IJK5 Strong Genetic Variation [259]
SORCS2 OTBF3DYK Strong Genetic Variation [128]
SORCS3 OT4VOMBC Strong Genetic Variation [169]
SPAG16 OTIFUPYD Strong Genetic Variation [169]
SPOCK3 OTYSOOO7 Strong Biomarker [278]
STATH OTQHBHM9 Strong Genetic Variation [68]
STT3A OTDPS6AV Strong Genetic Variation [151]
STUB1 OTSUYI9A Strong Biomarker [279]
STX1A OTSBUZB4 Strong Biomarker [280]
SYNE1 OTSBSLUH Strong Genetic Variation [151]
SYNM OTOI8TRJ Strong Biomarker [281]
SYT2 OTJYGTY4 Strong Genetic Variation [282]
TAL1 OTX4K6QZ Strong Genetic Variation [163]
TCF4 OTB9ASTK Strong Genetic Variation [151]
TENM4 OT91K3FC Strong Genetic Variation [151]
THBS3 OTDKMUBD Strong Biomarker [283]
THEM4 OTSIZU8Y Strong Biomarker [284]
THRSP OTKYE01L Strong Altered Expression [285]
TNR OTVJGAFN Strong Genetic Variation [258]
TPSG1 OTDESHKT Strong Biomarker [286]
TRIM25 OT35SG1R Strong Biomarker [287]
TRIM26 OTS0DJIP Strong Genetic Variation [151]
TRIM31 OT7VW6RP Strong Genetic Variation [288]
TRIM32 OTJOV0PG Strong Genetic Variation [269]
TSHZ1 OTYQ9ECW Strong Genetic Variation [289]
TSPAN31 OT8WQ83R Strong Biomarker [243]
TSPAN8 OT1F68WQ Strong Genetic Variation [242]
TTC12 OTDB24YV Strong Genetic Variation [290]
ADAMTS2 OTTK22NO Definitive Biomarker [291]
AUTS2 OTAEXHSC Definitive Genetic Variation [292]
BPIFA2 OTLFSDZD Definitive Biomarker [293]
CPLX2 OTU5QWFH Definitive Genetic Variation [294]
CYP2D7 OTYJTL3S Definitive Biomarker [295]
DOCK3 OTF3YS2W Definitive Biomarker [296]
EAF2 OTSOET5L Definitive Biomarker [297]
FMR1 OTWEV0T5 Definitive Genetic Variation [298]
GABRB3 OT80C3D4 Definitive Genetic Variation [299]
IQSEC2 OTYFRM4Q Definitive Genetic Variation [300]
ITIH3 OT4SLMLY Definitive Genetic Variation [158]
PSPH OTV1PVAX Definitive Biomarker [293]
PSPN OT54LLZJ Definitive Biomarker [293]
RAB3A OT2GIUO5 Definitive Biomarker [301]
RIDA OTW4098I Definitive Biomarker [293]
SDHA OTOJ8QFF Definitive CausalMutation [302]
SLITRK1 OT1QQ7FR Definitive Biomarker [303]
STXBP3 OTTTYMAQ Definitive Biomarker [293]
TRIT1 OTCU9FS5 Definitive Genetic Variation [304]
------------------------------------------------------------------------------------
⏷ Show the Full List of 219 DOT(s)

References

1 ClinicalTrials.gov (NCT00596908) 123I-ALTROPANE Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor. U.S. National Institutes of Health.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7118).
4 Clonidine FDA Label
5 Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents, 2009. FDA Approved - September 2, 2009
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2399).
8 Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7213).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4803).
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7236).
12 Guanfacine FDA Label
13 ClinicalTrials.gov (NCT04786990) Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD (ADHD). U.S. National Institutes of Health.
14 ClinicalTrials.gov (NCT00881452) A Trial of CM-AT in Children With Autism. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT03605849) A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. U.S. National Institutes of Health.
16 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 700249978)
17 ClinicalTrials.gov (NCT01323192) An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder. U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT03460652) KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD. U.S. National Institutes of Health.
19 Clinical pipeline report, company report or official report of KemPharm.
20 Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
21 ClinicalTrials.gov (NCT01654250) NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040591)
23 ClinicalTrials.gov (NCT01201187) Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD. U.S. National Institutes of Health.
24 The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75.
25 ClinicalTrials.gov (NCT01876719) AR08 for Treatment of ADHD in Children. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT00566449) A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.. U.S. National Institutes of Health.
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028722)
28 ClinicalTrials.gov (NCT01939353) An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder. U.S. National Institutes of Health.
29 ClinicalTrials.gov (NCT02884544) A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103). U.S. National Institutes of Health.
30 Clinical pipeline report, company report or official report of NLS Pharmaceutics
31 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
32 ClinicalTrials.gov (NCT03324581) The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder. U.S. National Institutes of Health.
33 ClinicalTrials.gov (NCT02699086) A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
34 Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63.
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038292)
36 ClinicalTrials.gov (NCT01174355) A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
37 Pharmaceutical Research Companies Are Developing Nearly 200 Medicines to Treat Mental Illnesses and Addictive Disorders. Pharmaceutical Research and Manufacturers of America report. 2012.
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030746)
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029714)
40 Clinical pipeline report, company report or official report of Tris Pharma.
41 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1244).
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026401)
44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030892)
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033282)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036290)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016245)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016618)
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1216).
50 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
51 Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
52 Meta-analysis of the DRD5 VNTR in persistent ADHD. Eur Neuropsychopharmacol. 2016 Sep;26(9):1527-1532. doi: 10.1016/j.euroneuro.2016.06.012. Epub 2016 Jul 29.
53 Synergistic effects between ADORA2A and DRD2 genes on anxiety disorders in children with ADHD.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:214-220. doi: 10.1016/j.pnpbp.2019.03.021. Epub 2019 Apr 1.
54 GJB2 mutations and additional disabilities in a pediatric cochlear implant population.Int J Pediatr Otorhinolaryngol. 2006 Mar;70(3):493-500. doi: 10.1016/j.ijporl.2005.07.026. Epub 2005 Sep 9.
55 The molecular genetic architecture of attention deficit hyperactivity disorder.Mol Psychiatry. 2015 Mar;20(3):289-97. doi: 10.1038/mp.2014.183. Epub 2015 Jan 20.
56 Association of Serotonin Receptors with Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis.Curr Med Sci. 2018 Jun;38(3):538-551. doi: 10.1007/s11596-018-1912-3. Epub 2018 Jun 22.
57 Attention Deficit Hyperactivity Disorder in Pediatric Patients with Pheochromocytoma and Paraganglioma.Horm Metab Res. 2016 Aug;48(8):509-13. doi: 10.1055/s-0042-106725. Epub 2016 May 12.
58 A genetic variant within STS previously associated with inattention in boys with attention deficit hyperactivity disorder is associated with enhanced cognition in healthy adult males.Brain Behav. 2017 Feb 9;7(3):e00646. doi: 10.1002/brb3.646. eCollection 2017 Mar.
59 Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis.Biol Psychiatry. 2017 Nov 1;82(9):634-641. doi: 10.1016/j.biopsych.2016.08.040. Epub 2016 Oct 18.
60 ADGRL3 (LPHN3) variants predict substance use disorder.Transl Psychiatry. 2019 Jan 29;9(1):42. doi: 10.1038/s41398-019-0396-7.
61 Efficacy and safety of the novel neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.Psychopharmacology (Berl). 2012 Feb;219(3):715-25. doi: 10.1007/s00213-011-2393-2. Epub 2011 Jul 12.
62 Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.Clin Pharmacol Ther. 2016 Jun;99(6):642-50. doi: 10.1002/cpt.319. Epub 2016 Jan 12.
63 Sensitivity to Peer Feedback in Young Adolescents with Symptoms of ADHD: Examination of Neurophysiological and Self-Report Measures.J Abnorm Child Psychol. 2019 Apr;47(4):605-617. doi: 10.1007/s10802-018-0470-2.
64 Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder.Nat Genet. 2011 Dec 4;44(1):78-84. doi: 10.1038/ng.1013.
65 Scanning of estrogen receptor alpha (ERalpha) and thyroid hormone receptor alpha (TRalpha) genes in patients with psychiatric diseases: four missense mutations identified in ERalpha gene.Am J Med Genet. 2001 May 8;105(4):369-74. doi: 10.1002/ajmg.1364.
66 Interaction effects of GIT1 and DRD4 gene variants on continuous performance test variables in patients with ADHD.Brain Behav. 2017 Aug 1;7(9):e00785. doi: 10.1002/brb3.785. eCollection 2017 Sep.
67 A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD.Psychopharmacology (Berl). 2013 Feb;225(4):895-902. doi: 10.1007/s00213-012-2875-x. Epub 2012 Sep 29.
68 Association between the alpha-2C-adrenergic receptor gene and attention deficit hyperactivity disorder in a Korean sample.Neurosci Lett. 2008 Dec 3;446(2-3):108-11. doi: 10.1016/j.neulet.2008.09.058.
69 Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
70 Deleterious Variation in BRSK2 Associates with a Neurodevelopmental Disorder. Am J Hum Genet. 2019 Apr 4;104(4):701-708. doi: 10.1016/j.ajhg.2019.02.002. Epub 2019 Mar 14.
71 Clinical features and genetic characterization of two dizygotic twins with C9orf72 expansion.Neurobiol Aging. 2018 Sep;69:293.e1-293.e8. doi: 10.1016/j.neurobiolaging.2018.05.002. Epub 2018 Jun 14.
72 CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms.Eur J Hum Genet. 2015 Nov;23(11):1505-12. doi: 10.1038/ejhg.2015.21. Epub 2015 Mar 4.
73 From Gene to Behavior: L-Type Calcium Channel Mechanisms Underlying Neuropsychiatric Symptoms.Neurotherapeutics. 2017 Jul;14(3):588-613. doi: 10.1007/s13311-017-0532-0.
74 Increased arterial pressure in mice with overexpression of the ADHD candidate gene calcyon in forebrain. PLoS One. 2019 Feb 12;14(2):e0211903. doi: 10.1371/journal.pone.0211903. eCollection 2019.
75 Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.Pharmacogenomics J. 2013 Oct;13(5):476-80. doi: 10.1038/tpj.2012.25. Epub 2012 Jun 12.
76 Impulsive aggression and response inhibition in attention-deficit/hyperactivity disorder and disruptive behavioral disorders: Findings from a systematic review.Neurosci Biobehav Rev. 2018 Jul;90:231-246. doi: 10.1016/j.neubiorev.2018.04.016. Epub 2018 Apr 22.
77 NAChR 42 Subtype and their Relation with Nicotine Addiction, Cognition, Depression and Hyperactivity Disorder.Curr Med Chem. 2019;26(20):3792-3811. doi: 10.2174/0929867325666180410105135.
78 Sex, ADHD symptoms, and CHRNA5 genotype influence reaction time but not response inhibition.J Neurosci Res. 2019 Feb;97(2):215-224. doi: 10.1002/jnr.24342. Epub 2018 Oct 12.
79 Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes.Sci Rep. 2017 Jan 3;7:39941. doi: 10.1038/srep39941.
80 Pleiotropic effects of Chr15q25 nicotinic gene cluster and the relationship between smoking, cognition and ADHD.J Psychiatr Res. 2016 Sep;80:73-78. doi: 10.1016/j.jpsychires.2016.06.002. Epub 2016 Jun 4.
81 Caffeine and cannabinoid receptors modulate impulsive behavior in an animal model of attentional deficit and hyperactivity disorder.Eur J Neurosci. 2019 Jun;49(12):1673-1683. doi: 10.1111/ejn.14348. Epub 2019 Feb 8.
82 Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder.Biol Psychiatry. 2008 May 15;63(10):935-45. doi: 10.1016/j.biopsych.2007.11.004. Epub 2008 Jan 7.
83 Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms.Neuropsychopharmacology. 2019 Jun;44(7):1198-1206. doi: 10.1038/s41386-019-0327-6. Epub 2019 Feb 6.
84 Hispanic Residential Isolation, ADHD Diagnosis and Stimulant Treatment among Medicaid-Insured Youth.Ethn Dis. 2017 Apr 20;27(2):85-94. doi: 10.18865/ed.27.2.85. eCollection 2017 Spring.
85 Expression of alternatively spliced variants of the Dclk1 gene is regulated by psychotropic drugs.BMC Neurosci. 2018 Sep 12;19(1):55. doi: 10.1186/s12868-018-0458-4.
86 Common and specific genes and peripheral biomarkers in children and adults with attention-deficit/hyperactivity disorder.World J Biol Psychiatry. 2018 Mar;19(2):80-100. doi: 10.1080/15622975.2017.1282175. Epub 2017 Feb 24.
87 Attention, cognitive control and motivation in ADHD: Linking event-related brain potentials and DNA methylation patterns in boys at early school age.Sci Rep. 2017 Jun 19;7(1):3823. doi: 10.1038/s41598-017-03326-3.
88 Inattention and Reaction Time Variability Are Linked to Ventromedial Prefrontal Volume in Adolescents.Biol Psychiatry. 2017 Nov 1;82(9):660-668. doi: 10.1016/j.biopsych.2017.01.003. Epub 2017 Jan 13.
89 A psycho-genetic study of associations between the symptoms of binge eating disorder and those of attention deficit (hyperactivity) disorder.J Psychiatr Res. 2009 Apr;43(7):687-96. doi: 10.1016/j.jpsychires.2008.10.010. Epub 2008 Nov 28.
90 Insertional translocation leading to a 4q13 duplication including the EPHA5 gene in two siblings with attention-deficit hyperactivity disorder.Am J Med Genet A. 2013 Aug;161A(8):1923-8. doi: 10.1002/ajmg.a.36032. Epub 2013 Jul 4.
91 Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET.Mol Psychiatry. 2021 Mar;26(3):1009-1018. doi: 10.1038/s41380-019-0461-x. Epub 2019 Aug 5.
92 Perinatal compromise contributes to programming of GABAergic and glutamatergic systems leading to long-term effects on offspring behaviour.J Neuroendocrinol. 2020 Jan;32(1):e12814. doi: 10.1111/jne.12814. Epub 2019 Dec 9.
93 Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy.Exp Neurol. 2017 Mar;289:64-72. doi: 10.1016/j.expneurol.2016.12.008. Epub 2016 Dec 22.
94 Attenuation of Novelty-Induced Hyperactivity of Gria1-/- Mice by Cannabidiol and Hippocampal Inhibitory Chemogenetics.Front Pharmacol. 2019 Mar 29;10:309. doi: 10.3389/fphar.2019.00309. eCollection 2019.
95 Altered -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor function and expression in hippocampus in a rat model of attention-deficit/hyperactivity disorder (ADHD).Behav Brain Res. 2019 Mar 15;360:209-215. doi: 10.1016/j.bbr.2018.12.028. Epub 2018 Dec 12.
96 Prediction of causal genes and gene expression analysis of attention-deficit hyperactivity disorder in the different brain region, a comprehensive integrative analysis of ADHD.Behav Brain Res. 2019 May 17;364:183-192. doi: 10.1016/j.bbr.2019.02.010. Epub 2019 Feb 6.
97 Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder.J Psychopharmacol. 2017 Aug;31(8):1070-1077. doi: 10.1177/0269881116667707. Epub 2016 Sep 13.
98 The effects of GRIN2B and DRD4 gene variants on local functional connectivity in attention-deficit/hyperactivity disorder.Brain Imaging Behav. 2018 Feb;12(1):247-257. doi: 10.1007/s11682-017-9690-2.
99 Glutamate receptor metabotropic 7 (GRM7) gene polymorphisms in mood disorders and attention deficit hyperactive disorder.Neurochem Int. 2019 Oct;129:104483. doi: 10.1016/j.neuint.2019.104483. Epub 2019 Jun 4.
100 Mouse knockout of guanylyl cyclase C: Recognition memory deficits in the absence of activity changes.Genes Brain Behav. 2019 Jun;18(5):e12573. doi: 10.1111/gbb.12573. Epub 2019 Apr 25.
101 A pilot trial of l-carnitine in patients with traumatic brain injury: Effects on biomarkers of injury.J Crit Care. 2018 Jun;45:128-132. doi: 10.1016/j.jcrc.2018.01.029. Epub 2018 Feb 9.
102 Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder.Neurol Sci. 2019 Mar;40(3):593-602. doi: 10.1007/s10072-018-3692-8. Epub 2019 Jan 7.
103 Relative Age and Attention-Deficit/Hyperactivity Disorder: Data From Three Epidemiological Cohorts and a Meta-analysis.J Am Acad Child Adolesc Psychiatry. 2020 Aug;59(8):990-997. doi: 10.1016/j.jaac.2019.07.939. Epub 2019 Aug 20.
104 Histamine H3 receptor antagonists ameliorate attention deficit/hyperactivity disorder-like behavioral changes caused by neonatal habenula lesion.Behav Pharmacol. 2018 Feb;29(1):71-78. doi: 10.1097/FBP.0000000000000343.
105 The serotonin 5-HT1D receptor gene and attention-deficit hyperactivity disorder in Chinese Han subjects.Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):874-6. doi: 10.1002/ajmg.b.30364.
106 Association of attention-deficit/hyperactivity disorder with serotonin 4 receptor gene polymorphisms in Han Chinese subjects.Neurosci Lett. 2006 Jun 19;401(1-2):6-9. doi: 10.1016/j.neulet.2006.02.053. Epub 2006 Mar 23.
107 No association of attention-deficit/hyperactivity disorder with genes of the serotonergic pathway in Han Chinese subjects.Neurosci Lett. 2006 Jul 31;403(1-2):172-5. doi: 10.1016/j.neulet.2006.04.036. Epub 2006 May 15.
108 The SNP-set based association study identifies ITGA1 as a susceptibility gene of attention-deficit/hyperactivity disorder in Han Chinese.Transl Psychiatry. 2017 Aug 15;7(8):e1201. doi: 10.1038/tp.2017.156.
109 Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies.J Neural Transm (Vienna). 2008 Nov;115(11):1573-85. doi: 10.1007/s00702-008-0119-3. Epub 2008 Oct 7.
110 Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysis.Eur Respir J. 2019 Dec 19;54(6):1901507. doi: 10.1183/13993003.01507-2019. Print 2019 Dec.
111 Attention-deficit/hyperactivity disorder associated with KChIP1 rs1541665 in Kv channels accessory proteins.PLoS One. 2017 Nov 27;12(11):e0188678. doi: 10.1371/journal.pone.0188678. eCollection 2017.
112 The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder.PLoS One. 2018 Nov 21;13(11):e0207750. doi: 10.1371/journal.pone.0207750. eCollection 2018.
113 ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.Pediatr Diabetes. 2017 Nov;18(7):518-523. doi: 10.1111/pedi.12428. Epub 2016 Aug 24.
114 Association of the KCNJ5 gene with Tourette Syndrome and Attention-Deficit/Hyperactivity Disorder.Genes Brain Behav. 2014 Jul;13(6):535-42. doi: 10.1111/gbb.12141. Epub 2014 Jun 19.
115 KCNJ6 variants modulate reward-related brain processes and impact executive functions in attention-deficit/hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet. 2020 Jul;183(5):247-257. doi: 10.1002/ajmg.b.32734. Epub 2019 May 17.
116 Prognostic factors in chronic lymphocytic leukemia.Curr Hematol Malig Rep. 2007 Feb;2(1):49-55. doi: 10.1007/s11899-007-0007-1.
117 Pilot study indicate role of preferentially transmitted monoamine oxidase gene variants in behavioral problems of male ADHD probands.BMC Med Genet. 2017 Oct 5;18(1):109. doi: 10.1186/s12881-017-0469-5.
118 Role of ADHD symptoms as a contributing factor to obesity in patients with MC4R mutations.Med Hypotheses. 2015 Jan;84(1):4-7. doi: 10.1016/j.mehy.2014.11.004. Epub 2014 Nov 15.
119 Neuropsychiatric "Comorbidity" as Causal Influence in Autism.J Am Acad Child Adolesc Psychiatry. 2020 Feb;59(2):229-235. doi: 10.1016/j.jaac.2019.07.008. Epub 2019 Jul 22.
120 Cortical thickness differences in the prefrontal cortex in children and adolescents with ADHD in relation to dopamine transporter (DAT1) genotype.Psychiatry Res. 2015 Sep 30;233(3):409-17. doi: 10.1016/j.pscychresns.2015.07.005. Epub 2015 Jul 8.
121 Genetic variations of the melatonin pathway in patients with attention-deficit and hyperactivity disorders.J Pineal Res. 2011 Nov;51(4):394-9. doi: 10.1111/j.1600-079X.2011.00902.x. Epub 2011 May 26.
122 Genetic variants of the folate metabolic system and mild hyperhomocysteinemia may affect ADHD associated behavioral problems.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):1-10. doi: 10.1016/j.pnpbp.2018.01.016. Epub 2018 Jan 31.
123 Polygenic transmission and complex neuro developmental network for attention deficit hyperactivity disorder: genome-wide association study of both common and rare variants.Am J Med Genet B Neuropsychiatr Genet. 2013 Jul;162B(5):419-430. doi: 10.1002/ajmg.b.32169. Epub 2013 May 31.
124 Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree.Mol Psychiatry. 2011 May;16(5):491-503. doi: 10.1038/mp.2010.29. Epub 2010 Mar 23.
125 A large-scale integrative analysis of GWAS and common meQTLs across whole life course identifies genes, pathways and tissue/cell types for three major psychiatric disorders.Neurosci Biobehav Rev. 2018 Dec;95:347-352. doi: 10.1016/j.neubiorev.2018.10.005. Epub 2018 Oct 16.
126 NURR1 deficiency is associated to ADHD-like phenotypes in mice.Transl Psychiatry. 2019 Aug 27;9(1):207. doi: 10.1038/s41398-019-0544-0.
127 Psychosocial, cognitive, and motor functioning in patients with suspected Sotos syndrome: a comparison between patients with and without NSD1 gene alterations.Dev Med Child Neurol. 2006 Jul;48(7):582-8. doi: 10.1017/S0012162206001228.
128 New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet. 2015 Sep;168(6):459-470. doi: 10.1002/ajmg.b.32341. Epub 2015 Jul 14.
129 Common obesity risk alleles in childhood attention-deficit/hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet. 2013 Jun;162B(4):295-305. doi: 10.1002/ajmg.b.32144. Epub 2013 Mar 26.
130 Gene-set and multivariate genome-wide association analysis of oppositional defiant behavior subtypes in attention-deficit/hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet. 2016 Jul;171(5):573-88. doi: 10.1002/ajmg.b.32346. Epub 2015 Jul 16.
131 PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.Cell Signal. 2019 Aug;60:31-38. doi: 10.1016/j.cellsig.2019.04.001. Epub 2019 Apr 2.
132 RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network ("Rhesactome") in the striatum.Sci Signal. 2016 Nov 15;9(454):ra111. doi: 10.1126/scisignal.aaf6670.
133 Acetylcholine-metabolizing butyrylcholinesterase (BCHE) copy number and single nucleotide polymorphisms and their role in attention-deficit/hyperactivity syndrome.J Psychiatr Res. 2013 Dec;47(12):1902-8. doi: 10.1016/j.jpsychires.2013.08.006. Epub 2013 Aug 30.
134 Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009 Jan;34(2):458-67.
135 Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):122-128. doi: 10.1016/j.pnpbp.2018.01.013. Epub 2018 Feb 20.
136 A functional variant in SLC1A3 influences ADHD risk by disrupting a hsa-miR-3171 binding site: A two-stage association study.Genes Brain Behav. 2019 Jun;18(5):e12574. doi: 10.1111/gbb.12574. Epub 2019 May 8.
137 Functional analysis of a triplet deletion in the gene encoding the sodium glucose transporter 3, a potential risk factor for ADHD.PLoS One. 2018 Oct 4;13(10):e0205109. doi: 10.1371/journal.pone.0205109. eCollection 2018.
138 SLC6A1 gene involvement in susceptibility to attention-deficit/hyperactivity disorder: A case-control study and gene-environment interaction.Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jul 3;77:202-208. doi: 10.1016/j.pnpbp.2017.04.015. Epub 2017 Apr 23.
139 Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality.Mol Psychiatry. 2020 Oct;25(10):2493-2503. doi: 10.1038/s41380-018-0339-3. Epub 2019 Jan 4.
140 Dehydroepiandrosterone sulfate, free testosterone, and sex hormone-binding globulin on susceptibility to attention-deficit/hyperactivity disorder.Psychoneuroendocrinology. 2019 May;103:212-218. doi: 10.1016/j.psyneuen.2019.01.025. Epub 2019 Jan 24.
141 A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.J Atten Disord. 2020 Jan;24(2):348-358. doi: 10.1177/1087054719836159. Epub 2019 Mar 29.
142 The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.J Psychopharmacol. 2016 Sep;30(9):848-55. doi: 10.1177/0269881116658992. Epub 2016 Jul 26.
143 Suggestive diagnosis of attention-deficit/hyperactivity disorder in indigenous children and adolescents from the Brazilian Amazon.Eur Child Adolesc Psychiatry. 2020 Mar;29(3):373-384. doi: 10.1007/s00787-019-01356-y. Epub 2019 Jun 4.
144 The role of epigenetic modifications in neurodevelopmental disorders: A systematic review.Neurosci Biobehav Rev. 2018 Nov;94:17-30. doi: 10.1016/j.neubiorev.2018.07.011. Epub 2018 Jul 29.
145 Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation.J Pediatr. 2012 Oct;161(4):705-9.e1. doi: 10.1016/j.jpeds.2012.03.020. Epub 2012 May 5.
146 Linkage study of polymorphisms in the gene for myelin oligodendrocyte glycoprotein located on chromosome 6p and attention deficit hyperactivity disorder.Am J Med Genet. 2001 Apr 8;105(3):250-4. doi: 10.1002/ajmg.1302.
147 Association between ambient gaseous and particulate air pollutants and attention deficit hyperactivity disorder (ADHD) in children; a systematic review.Environ Res. 2019 Jun;173:135-156. doi: 10.1016/j.envres.2019.03.030. Epub 2019 Mar 15.
148 Case-control genome-wide association study of attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):906-20. doi: 10.1016/j.jaac.2010.06.007. Epub 2010 Aug 5.
149 The screening of SLC6A8 deficiency among Estonian families with X-linked mental retardation.J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S5-11. doi: 10.1007/s10545-008-1063-y.
150 Low intelligence but not attention deficit hyperactivity disorder is associated with resistance to thyroid hormone caused by mutation R316H in the thyroid hormone receptor beta gene.J Clin Endocrinol Metab. 1994 Jun;78(6):1525-8. doi: 10.1210/jcem.78.6.8200958.
151 Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.Lancet. 2013 Apr 20;381(9875):1371-1379. doi: 10.1016/S0140-6736(12)62129-1. Epub 2013 Feb 28.
152 The DAO gene is associated with schizophrenia and interacts with other genes in the Taiwan Han Chinese population.PLoS One. 2013;8(3):e60099. doi: 10.1371/journal.pone.0060099. Epub 2013 Mar 28.
153 Generation of a human induced pluripotent stem cell (iPSC) line from a 51-year-old female with attention-deficit/hyperactivity disorder (ADHD) carrying a duplication of SLC2A3.Stem Cell Res. 2018 Apr;28:136-140. doi: 10.1016/j.scr.2018.02.005. Epub 2018 Feb 13.
154 Manganese transporter genetics and sex modify the association between environmental manganese exposure and neurobehavioral outcomes in children.Environ Int. 2019 Sep;130:104908. doi: 10.1016/j.envint.2019.104908. Epub 2019 Jun 22.
155 The Na(+)(K(+))/H(+) exchanger Nhx1 controls multivesicular body-vacuolar lysosome fusion.Mol Biol Cell. 2018 Feb 1;29(3):317-325. doi: 10.1091/mbc.E17-08-0496. Epub 2017 Dec 6.
156 A mouse model of autism implicates endosome pH in the regulation of presynaptic calcium entry.Nat Commun. 2018 Jan 23;9(1):330. doi: 10.1038/s41467-017-02716-5.
157 Phenotypically distinct subtypes of psychosis accompany novel or rare variants in four different signaling genes.EBioMedicine. 2016 Apr;6:206-214. doi: 10.1016/j.ebiom.2016.03.008. Epub 2016 Mar 8.
158 Family-based association study of the arsenite methyltransferase gene (AS3MT, rs11191454) in Korean children with attention-deficit hyperactivity disorder.Psychiatr Genet. 2015 Feb;25(1):26-30. doi: 10.1097/YPG.0000000000000064.
159 CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51. doi: 10.1097/01.chi.0000246056.83791.b6.
160 The first evidence of an association between a polymorphism in the endocannabinoid-degrading enzyme FAAH (FAAH rs2295633) with attention deficit hyperactivity disorder.Genomics. 2020 Mar;112(2):1330-1334. doi: 10.1016/j.ygeno.2019.07.024. Epub 2019 Aug 1.
161 Angiogenic, neurotrophic, and inflammatory system SNPs moderate the association between birth weight and ADHD symptom severity.Am J Med Genet B Neuropsychiatr Genet. 2014 Dec;165B(8):691-704. doi: 10.1002/ajmg.b.32275. Epub 2014 Oct 25.
162 Rotenone exerts developmental neurotoxicity in a human brain spheroid model.Toxicol Appl Pharmacol. 2018 Sep 1;354:101-114. doi: 10.1016/j.taap.2018.02.003. Epub 2018 Feb 8.
163 Relationship of Probable Attention Deficit Hyperactivity Disorder with Severity of Psychopathology and Impulsivity in a Sample of Male Patients with Opioid Use Disorder.Psychiatry Investig. 2018 Feb;15(2):164-171. doi: 10.30773/pi.2017.05.14.1. Epub 2017 Dec 1.
164 Association Between Prematurity and Diagnosis of Neurodevelopment Disorder: A Case-Control Study.J Autism Dev Disord. 2020 Jan;50(1):145-152. doi: 10.1007/s10803-019-04235-2.
165 De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.Eur J Med Genet. 2019 Jan;62(1):55-60. doi: 10.1016/j.ejmg.2018.05.003. Epub 2018 May 22.
166 Attention deficit hyperactivity disorder symptoms in patients with cystic fibrosis.J Cyst Fibros. 2018 Mar;17(2):281-285. doi: 10.1016/j.jcf.2017.11.020. Epub 2017 Dec 19.
167 Severe combined immunodeficiency (SCID) and attention deficit hyperactivity disorder (ADHD) associated with a Coronin-1A mutation and a chromosome 16p11.2 deletion.Clin Immunol. 2009 Apr;131(1):24-30. doi: 10.1016/j.clim.2008.11.002. Epub 2008 Dec 20.
168 Emotion Regulation via the Autonomic Nervous System in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Replication and Extension.J Abnorm Child Psychol. 2020 Mar;48(3):361-373. doi: 10.1007/s10802-019-00593-8.
169 Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder.Nat Genet. 2019 Jan;51(1):63-75. doi: 10.1038/s41588-018-0269-7. Epub 2018 Nov 26.
170 Antecedent ADHD, dementia, and metabolic dysregulation: A U.S. based cohort analysis.Neurochem Int. 2018 Jan;112:255-258. doi: 10.1016/j.neuint.2017.08.005. Epub 2017 Aug 12.
171 Phenotypic spectrum of eleven patients and five novel MTFMT mutations identified by exome sequencing and candidate gene screening.Mol Genet Metab. 2014 Mar;111(3):342-352. doi: 10.1016/j.ymgme.2013.12.010. Epub 2013 Dec 25.
172 Astrocyte-specific NDRG2 gene: functions in the brain and neurological diseases.Cell Mol Life Sci. 2020 Jul;77(13):2461-2472. doi: 10.1007/s00018-019-03406-9. Epub 2019 Dec 13.
173 Altered kynurenine pathway metabolites in a mouse model of human attention-deficit hyperactivity/autism spectrum disorders: A potential new biological diagnostic marker.Sci Rep. 2019 Sep 12;9(1):13182. doi: 10.1038/s41598-019-49781-y.
174 A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder.Biol Psychiatry. 2018 Jun 15;83(12):1044-1053. doi: 10.1016/j.biopsych.2017.11.026. Epub 2017 Dec 2.
175 Interactions between MAOA and SYP polymorphisms were associated with symptoms of attention-deficit/hyperactivity disorder in Chinese Han subjects.Am J Med Genet B Neuropsychiatr Genet. 2015 Jan;168B(1):45-53. doi: 10.1002/ajmg.b.32273. Epub 2014 Dec 8.
176 Clock genes, ADHD and aggression.Neurosci Biobehav Rev. 2018 Aug;91:51-68. doi: 10.1016/j.neubiorev.2016.11.002. Epub 2016 Nov 9.
177 A current view on contactin-4, -5, and -6: Implications in neurodevelopmental disorders.Mol Cell Neurosci. 2017 Jun;81:72-83. doi: 10.1016/j.mcn.2016.12.004. Epub 2017 Jan 5.
178 Aarskog-Scott syndrome: a novel mutation in the FGD1 gene associated with severe craniofacial dysplasia.Eur J Pediatr. 2014 Oct;173(10):1373-6. doi: 10.1007/s00431-014-2317-3. Epub 2014 Apr 27.
179 Primate-accelerated evolutionary genes: novel routes to drug discovery in psychiatric disorders.Curr Med Chem. 2010;17(13):1300-16. doi: 10.2174/092986710790936338.
180 De novo mutations in MED13, a component of the Mediator complex, are associated with a novel neurodevelopmental disorder. Hum Genet. 2018 May;137(5):375-388. doi: 10.1007/s00439-018-1887-y. Epub 2018 May 8.
181 Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes.Mol Psychiatry. 2010 Jun;15(6):637-46. doi: 10.1038/mp.2009.57. Epub 2009 Jun 23.
182 Structural variants in the retinoid receptor genes in patients with schizophrenia and other psychiatric diseases.Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):50-3. doi: 10.1002/ajmg.b.30113.
183 Genome-wide analyses of aggressiveness in attention-deficit hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet. 2016 Jul;171(5):733-47. doi: 10.1002/ajmg.b.32434. Epub 2016 Mar 29.
184 A long-term follow-up study of men born with very low birth weight and their reproductive hormone profile.Syst Biol Reprod Med. 2018 Jun;64(3):207-215. doi: 10.1080/19396368.2018.1448901. Epub 2018 Mar 27.
185 Regulating the Regulators in Attention-Deficit/Hyperactivity Disorder: A Genetic Association Study of microRNA Biogenesis Pathways.OMICS. 2017 Jun;21(6):352-358. doi: 10.1089/omi.2017.0048. Epub 2017 May 30.
186 Early-Onset Efficacy and Safety Pilot Study of Amphetamine Extended-Release Oral Suspension in the Treatment of Children with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2019 Feb;29(1):2-8. doi: 10.1089/cap.2018.0078. Epub 2018 Dec 21.
187 A preliminary study on methylphenidate-regulated gene expression in lymphoblastoid cells of ADHD patients.World J Biol Psychiatry. 2015 Apr;16(3):180-9. doi: 10.3109/15622975.2014.948064. Epub 2014 Aug 27.
188 The Atxn7-overexpressing mice showed hyperactivity and impulsivity which were ameliorated by atomoxetine treatment: A possible animal model of the hyperactive-impulsive phenotype of ADHD.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:311-319. doi: 10.1016/j.pnpbp.2018.08.012. Epub 2018 Aug 17.
189 Integrated Analysis of microRNA and mRNA Expression Profiles: An Attempt to Disentangle the Complex Interaction Network in Attention Deficit Hyperactivity Disorder.Brain Sci. 2019 Oct 22;9(10):288. doi: 10.3390/brainsci9100288.
190 Genome-Wide Association Studies of Impulsive Personality Traits (BIS-11 and UPPS-P) and Drug Experimentation in up to 22,861 Adult Research Participants Identify Loci in the CACNA1I and CADM2 genes.J Neurosci. 2019 Mar 27;39(13):2562-2572. doi: 10.1523/JNEUROSCI.2662-18.2019. Epub 2019 Feb 4.
191 Inter-hemispherical asymmetry in default-mode functional connectivity and BAIAP2 gene are associated with anger expression in ADHD adults.Psychiatry Res Neuroimaging. 2017 Nov 30;269:54-61. doi: 10.1016/j.pscychresns.2017.09.004. Epub 2017 Sep 12.
192 Screening for adult attention-deficit/hyperactivity disorder in alcohol dependent patients: Underreporting of ADHD symptoms in self-report scales.Drug Alcohol Depend. 2019 Feb 1;195:52-58. doi: 10.1016/j.drugalcdep.2018.11.020. Epub 2018 Dec 10.
193 Decreased parvalbumin and somatostatin neurons in medial prefrontal cortex in BRINP1-KO mice.Neurosci Lett. 2018 Sep 14;683:82-88. doi: 10.1016/j.neulet.2018.06.050. Epub 2018 Jun 28.
194 Exploring the genetic link between RLS and ADHD.J Psychiatr Res. 2009 Jul;43(10):941-5. doi: 10.1016/j.jpsychires.2009.01.003. Epub 2009 Feb 14.
195 Cocaine and amphetamine regulated transcript (CART) in suicide attempters.Psychiatry Res. 2008 Mar 15;158(2):117-22. doi: 10.1016/j.psychres.2007.06.031. Epub 2007 Dec 21.
196 Reduced neonatal brain-derived neurotrophic factor is associated with autism spectrum disorders.Transl Psychiatry. 2019 Oct 7;9(1):252. doi: 10.1038/s41398-019-0587-2.
197 Early-life stress impairs developmental programming in Cadherin 13 (CDH13)-deficient mice.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:158-168. doi: 10.1016/j.pnpbp.2018.08.010. Epub 2018 Aug 28.
198 Mice lacking cyclin-dependent kinase-like 5 manifest autistic and ADHD-like behaviors.Hum Mol Genet. 2017 Oct 15;26(20):3922-3934. doi: 10.1093/hmg/ddx279.
199 Family-based genome-wide association scan of attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2010 Sep;49(9):898-905.e3. doi: 10.1016/j.jaac.2010.02.014. Epub 2010 May 14.
200 Nicotinic receptor gene variants interact with attention deficient hyperactive disorder symptoms to predict smoking trajectories from early adolescence to adulthood.Addict Behav. 2013 Nov;38(11):2683-9. doi: 10.1016/j.addbeh.2013.06.013. Epub 2013 Jul 1.
201 Disruption of the ATXN1-CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans. Nat Genet. 2017 Apr;49(4):527-536. doi: 10.1038/ng.3808. Epub 2017 Mar 13.
202 Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample.Mol Psychiatry. 2014 May;19(5):615-24. doi: 10.1038/mp.2013.72. Epub 2013 Jun 11.
203 Cross-species models of attention-deficit/hyperactivity disorder and autism spectrum disorder: lessons from CNTNAP2, ADGRL3, and PARK2.Psychiatr Genet. 2019 Feb;29(1):1-17. doi: 10.1097/YPG.0000000000000211.
204 Auditory processing and neuropsychological profiles of children with functional hearing loss.Int J Pediatr Otorhinolaryngol. 2018 Nov;114:51-60. doi: 10.1016/j.ijporl.2018.07.054. Epub 2018 Jul 31.
205 ADHD and poor motor performance from a family genetic perspective.J Am Acad Child Adolesc Psychiatry. 2009 Jan;48(1):25-34. doi: 10.1097/CHI.0b013e31818b1ca2.
206 Genetic association study of dyslexia and ADHD candidate genes in a Spanish cohort: Implications of comorbid samples.PLoS One. 2018 Oct 31;13(10):e0206431. doi: 10.1371/journal.pone.0206431. eCollection 2018.
207 Expressional profile of the diacylglycerol kinase eta gene DGKH.Eur Arch Psychiatry Clin Neurosci. 2017 Aug;267(5):445-454. doi: 10.1007/s00406-016-0695-4. Epub 2016 Apr 16.
208 Expression of the ADHD candidate gene Diras2 in the brain.J Neural Transm (Vienna). 2018 Jun;125(6):913-923. doi: 10.1007/s00702-018-1867-3. Epub 2018 Feb 27.
209 DLGAP1 and NMDA receptor-associated postsynaptic density protein genes influence executive function in attention deficit hyperactivity disorder.Brain Behav. 2018 Jan 23;8(2):e00914. doi: 10.1002/brb3.914. eCollection 2018 Feb.
210 Controlled, blindly rated, direct-interview family study of a prepubertal and early-adolescent bipolar I disorder phenotype: morbid risk, age at onset, and comorbidity.Arch Gen Psychiatry. 2006 Oct;63(10):1130-8. doi: 10.1001/archpsyc.63.10.1130.
211 Heterogeneous clinical spectrum of DNAJC12-deficient hyperphenylalaninemia: from attention deficit to severe dystonia and intellectual disability.J Med Genet. 2017 Aug 9:jmedgenet-2017-104875. doi: 10.1136/jmedgenet-2017-104875. Online ahead of print.
212 Association of genetic variations in DTNBP1 with cognitive function in schizophrenia patients and healthy subjects.Am J Med Genet B Neuropsychiatr Genet. 2012 Oct;159B(7):841-9. doi: 10.1002/ajmg.b.32091. Epub 2012 Aug 22.
213 Elfn1 recruits presynaptic mGluR7 in trans and its loss results in seizures.Nat Commun. 2014 Jul 22;5:4501. doi: 10.1038/ncomms5501.
214 Case-control genome-wide association study of persistent attention-deficit hyperactivity disorder identifies FBXO33 as a novel susceptibility gene for the disorder.Neuropsychopharmacology. 2015 Mar;40(4):915-26. doi: 10.1038/npp.2014.267. Epub 2014 Oct 6.
215 Genome-wide association study of the child behavior checklist dysregulation profile.J Am Acad Child Adolesc Psychiatry. 2011 Aug;50(8):807-17.e8. doi: 10.1016/j.jaac.2011.05.001. Epub 2011 Jul 13.
216 Gene-based analysis of ADHD using PASCAL: a biological insight into the novel associated genes.BMC Med Genomics. 2019 Oct 24;12(1):143. doi: 10.1186/s12920-019-0593-5.
217 Striatal transcriptome of a mouse model of ADHD reveals a pattern of synaptic remodeling.PLoS One. 2018 Aug 15;13(8):e0201553. doi: 10.1371/journal.pone.0201553. eCollection 2018.
218 Loss of Frrs1l disrupts synaptic AMPA receptor function, and results in neurodevelopmental, motor, cognitive and electrographical abnormalities.Dis Model Mech. 2019 Feb 22;12(2):dmm036806. doi: 10.1242/dmm.036806.
219 Locus-specific DNA methylation changes and phenotypic variability in children with attention-deficit hyperactivity disorder.Psychiatry Res. 2017 Oct;256:298-304. doi: 10.1016/j.psychres.2017.06.048. Epub 2017 Jun 20.
220 GIT1 regulates synaptic structural plasticity underlying learning.PLoS One. 2018 Mar 19;13(3):e0194350. doi: 10.1371/journal.pone.0194350. eCollection 2018.
221 Disturbed neurotransmitter homeostasis in ether lipid deficiency.Hum Mol Genet. 2019 Jun 15;28(12):2046-2061. doi: 10.1093/hmg/ddz040.
222 A novel maternally inherited 8q24.3 and a rare paternally inherited 14q23.3 CNVs in a family with neurodevelopmental disorders.Am J Med Genet A. 2015 Aug;167A(8):1921-6. doi: 10.1002/ajmg.a.37110. Epub 2015 Apr 10.
223 Longitudinal Evaluation of the Cognitive-Behavioral Model of ADHD in a Sample of College Students With ADHD.J Atten Disord. 2018 Feb;22(4):323-333. doi: 10.1177/1087054715616184. Epub 2015 Dec 4.
224 Mitochondrial-associated protein biomarkers in patients with attention-deficit/hyperactivity disorder.Mitochondrion. 2019 Nov;49:83-88. doi: 10.1016/j.mito.2019.07.007. Epub 2019 Jul 23.
225 Baseline Neurocognitive Performance and Symptoms in Those With Attention Deficit Hyperactivity Disorders and History of Concussion With Previous Loss of Consciousness.Front Neurol. 2019 Apr 24;10:396. doi: 10.3389/fneur.2019.00396. eCollection 2019.
226 Significant association between rare IPO11-HTR1A variants and attention deficit hyperactivity disorder in Caucasians.Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):544-56. doi: 10.1002/ajmg.b.32329. Epub 2015 Jun 16.
227 The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment.J Pediatr Hematol Oncol. 2017 Apr;39(3):174-178. doi: 10.1097/MPH.0000000000000761.
228 Vibrio cholerae FeoB contains a dual nucleotide-specific NTPase domain essential for ferrous iron uptake.Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4599-4604. doi: 10.1073/pnas.1817964116. Epub 2019 Feb 13.
229 KCNIP4 as a candidate gene for personality disorders and adult ADHD.Eur Neuropsychopharmacol. 2013 Jun;23(6):436-47. doi: 10.1016/j.euroneuro.2012.07.017. Epub 2012 Sep 14.
230 Pediatric bipolar disorder and ADHD: family history comparison in the LAMS clinical sample.J Affect Disord. 2012 Dec 10;141(2-3):382-9. doi: 10.1016/j.jad.2012.03.015. Epub 2012 Mar 31.
231 Hyperactive behavior in a family with autosomal dominant lateral temporal lobe epilepsy caused by a mutation in the LGI1/epitempin gene.Epilepsy Behav. 2013 Jul;28(1):41-6. doi: 10.1016/j.yebeh.2013.03.032. Epub 2013 May 5.
232 Association study of brain-derived neurotrophic factor (BDNF) and LIN-7 homolog (LIN-7) genes with adult attention-deficit/hyperactivity disorder.Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):945-51. doi: 10.1002/ajmg.b.30723.
233 Bipolar disorder risk alleles in children with ADHD.J Neural Transm (Vienna). 2013 Nov;120(11):1611-7. doi: 10.1007/s00702-013-1035-8. Epub 2013 May 28.
234 Increased symptoms of attention deficit hyperactivity disorder and major depressive disorder symptoms in Nail-patella syndrome: potential association with LMX1B loss-of-function.Am J Med Genet B Neuropsychiatr Genet. 2011 Jan;156B(1):59-66. doi: 10.1002/ajmg.b.31138. Epub 2010 Nov 2.
235 Screening with an ADHD-specific rating scale in preschoolers: A cross-cultural comparison of the Early Childhood Inventory-4.Psychol Assess. 2019 Aug;31(8):985-994. doi: 10.1037/pas0000722. Epub 2019 Apr 8.
236 MAP1B and NOS1 genes are associated with working memory in youths with attention-deficit/hyperactivity disorder.Eur Arch Psychiatry Clin Neurosci. 2016 Jun;266(4):359-66. doi: 10.1007/s00406-015-0626-9. Epub 2015 Aug 2.
237 Expanding the phenotypic spectrum of MBOAT7-related intellectual disability.Am J Med Genet B Neuropsychiatr Genet. 2019 Oct;180(7):483-487. doi: 10.1002/ajmg.b.32749. Epub 2019 Jul 8.
238 A new locus regulating MICALL2 expression was identified for association with executive inhibition in children with attention deficit hyperactivity disorder.Mol Psychiatry. 2018 Apr;23(4):1014-1020. doi: 10.1038/mp.2017.74. Epub 2017 Apr 18.
239 Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.JAMA Dermatol. 2016 Apr;152(4):405-12. doi: 10.1001/jamadermatol.2015.4356.
240 Surface-based shared and distinct resting functional connectivity in attention-deficit hyperactivity disorder and autism spectrum disorder.Br J Psychiatry. 2019 Jun;214(6):339-344. doi: 10.1192/bjp.2018.248.
241 Latent Class Analysis of ADHD Neurodevelopmental and Mental Health Comorbidities.J Dev Behav Pediatr. 2018 Jan;39(1):10-19. doi: 10.1097/DBP.0000000000000508.
242 Bipolar disorder risk alleles in adult ADHD patients.Genes Brain Behav. 2011 Jun;10(4):418-23. doi: 10.1111/j.1601-183X.2011.00680.x. Epub 2011 Feb 18.
243 Training Executive, Attention, and Motor Skills (TEAMS): a Preliminary Randomized Clinical Trial of Preschool Youth with ADHD.J Abnorm Child Psychol. 2020 Mar;48(3):375-389. doi: 10.1007/s10802-019-00610-w.
244 Shati/Nat8l knockout mice show behavioral deficits ameliorated by atomoxetine and methylphenidate.Behav Brain Res. 2018 Feb 26;339:207-214. doi: 10.1016/j.bbr.2017.11.040. Epub 2017 Dec 2.
245 The relationship between the presence of ADHD and certain candidate gene polymorphisms in a Turkish sample.Gene. 2013 Oct 10;528(2):320-7. doi: 10.1016/j.gene.2013.07.004. Epub 2013 Jul 18.
246 Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use.Allergy. 2018 Mar;73(3):615-626. doi: 10.1111/all.13326. Epub 2017 Nov 20.
247 Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder.Int J Neuropsychopharmacol. 2013 Apr;16(3):549-56. doi: 10.1017/S1461145712000697. Epub 2012 Jul 25.
248 Association of attention-deficit/hyperactivity disorder with a candidate region for reading disabilities on chromosome 6p.Biol Psychiatry. 2009 Aug 15;66(4):368-75. doi: 10.1016/j.biopsych.2009.02.016. Epub 2009 Apr 11.
249 Attention-deficit hyperactivity disorder shares copy number variant risk with schizophrenia and autism spectrum disorder.Transl Psychiatry. 2019 Oct 17;9(1):258. doi: 10.1038/s41398-019-0599-y.
250 Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.Cereb Cortex. 2009 Jul;19(7):1515-20. doi: 10.1093/cercor/bhn159. Epub 2008 Sep 11.
251 Disruption of the homeodomain transcription factor orthopedia homeobox (Otp) is associated with obesity and anxiety.Mol Metab. 2017 Nov;6(11):1419-1428. doi: 10.1016/j.molmet.2017.08.006. Epub 2017 Aug 24.
252 The HIDEA School-Based Screening Scale for Teachers to Detect ADHD Markers in Elementary Students.Psicothema. 2017 Aug;29(3):329-334. doi: 10.7334/psicothema2016.246.
253 "When the Prescription Pad Is Not Enough": Attention-Deficit Hyperactivity Disorder Management 2.0.J Dev Behav Pediatr. 2017 Feb/Mar;38 Suppl 1:S32-S34. doi: 10.1097/DBP.0000000000000403.
254 Parent-of-origin effects of FAS and PDLIM1 in attention-deficit/hyperactivity disorder.J Psychiatry Neurosci. 2012 Jan;37(1):46-52. doi: 10.1503/jpn.100173.
255 Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study.Mol Psychiatry. 2017 Feb;22(2):250-256. doi: 10.1038/mp.2016.85. Epub 2016 May 24.
256 Psychometric Properties and Factor Structure of the Short Form of the Affective Lability Scale in Adult Patients With ADHD.J Atten Disord. 2019 Aug;23(10):1079-1089. doi: 10.1177/1087054717690808. Epub 2017 Feb 2.
257 Effects of circadian clock protein Per1b on zebrafish visual functions.Chronobiol Int. 2018 Feb;35(2):160-168. doi: 10.1080/07420528.2017.1391276. Epub 2017 Nov 20.
258 A case-control genome-wide association study of ADHD discovers a novel association with the tenascin R (TNR) gene.Transl Psychiatry. 2018 Dec 18;8(1):284. doi: 10.1038/s41398-018-0329-x.
259 Exploring genetic variation that influences brain methylation in attention-deficit/hyperactivity disorder.Transl Psychiatry. 2019 Oct 3;9(1):242. doi: 10.1038/s41398-019-0574-7.
260 Does parental expressed emotion moderate genetic effects in ADHD? An exploration using a genome wide association scan.Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1359-68. doi: 10.1002/ajmg.b.30860.
261 A Upf3b-mutant mouse model with behavioral and neurogenesis defects.Mol Psychiatry. 2018 Aug;23(8):1773-1786. doi: 10.1038/mp.2017.173. Epub 2017 Sep 26.
262 A study on association of iron deficiency with attention deficit hyperactivity disorder in a tertiary care center.Indian J Psychiatry. 2018 Jan-Mar;60(1):131-134. doi: 10.4103/psychiatry.IndianJPsychiatry_197_17.
263 Understanding the Epilepsy in POLG Related Disease.Int J Mol Sci. 2017 Aug 24;18(9):1845. doi: 10.3390/ijms18091845.
264 A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.J Child Adolesc Psychopharmacol. 2017 Mar;27(2):112-116. doi: 10.1089/cap.2016.0124. Epub 2016 Nov 4.
265 Specificity of executive function and theory of mind performance in relation to attention-deficit/hyperactivity symptoms in autism spectrum disorders.Mol Autism. 2017 Nov 9;8:60. doi: 10.1186/s13229-017-0177-1. eCollection 2017.
266 Identification of ADHD risk genes in extended pedigrees by combining linkage analysis and whole-exome sequencing.Mol Psychiatry. 2020 Sep;25(9):2047-2057. doi: 10.1038/s41380-018-0210-6. Epub 2018 Aug 16.
267 Exome chip analyses in adult attention deficit hyperactivity disorder.Transl Psychiatry. 2016 Oct 18;6(10):e923. doi: 10.1038/tp.2016.196.
268 Sleep phenotypes in attention deficit hyperactivity disorder.Sleep Med. 2019 Aug;60:123-131. doi: 10.1016/j.sleep.2018.08.026. Epub 2018 Sep 20.
269 Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD.Sci Transl Med. 2011 Aug 10;3(95):95ra75. doi: 10.1126/scitranslmed.3002464.
270 Genetic Markers of ADHD-Related Variations in Intracranial Volume.Am J Psychiatry. 2019 Mar 1;176(3):228-238. doi: 10.1176/appi.ajp.2018.18020149.
271 Sleep alterations in pediatric bipolar disorder versus attention deficit disorder.Psychiatry Res. 2019 May;275:39-45. doi: 10.1016/j.psychres.2019.01.108. Epub 2019 Mar 7.
272 Gene-wide Association Study Reveals RNF122 Ubiquitin Ligase as a Novel Susceptibility Gene for Attention Deficit Hyperactivity Disorder.Sci Rep. 2017 Jul 14;7(1):5407. doi: 10.1038/s41598-017-05514-7.
273 Co-transmission of conduct problems with attention-deficit/hyperactivity disorder: familial evidence for a distinct disorder.J Neural Transm (Vienna). 2008;115(2):163-75. doi: 10.1007/s00702-007-0837-y. Epub 2008 Jan 16.
274 Mutations in SCAPER cause autosomal recessive retinitis pigmentosa with intellectual disability. J Med Genet. 2017 Sep 18;54(10):698-704. doi: 10.1136/jmedgenet-2017-104632. Epub 2017 Aug 9.
275 A Systematic Review and Evaluation of Clinical Practice Guidelines for Children and Youth with Disruptive Behavior: Rigor of Development and Recommendations for Use.Clin Child Fam Psychol Rev. 2019 Dec;22(4):527-548. doi: 10.1007/s10567-019-00292-2.
276 Screening for Attention-Deficit/Hyperactivity Disorder and Comorbidities in a Diverse, Urban Primary Care Setting.Clin Pediatr (Phila). 2018 Oct;57(12):1442-1452. doi: 10.1177/0009922818787329. Epub 2018 Jul 13.
277 Effects of SHP465 mixed amphetamine salts in adults with ADHD in a simulated adult workplace environment.Postgrad Med. 2018 Jan;130(1):111-121. doi: 10.1080/00325481.2018.1389227. Epub 2017 Oct 31.
278 SPOCK3, a risk gene for adult ADHD and personality disorders.Eur Arch Psychiatry Clin Neurosci. 2014 Aug;264(5):409-21. doi: 10.1007/s00406-013-0476-2. Epub 2013 Nov 29.
279 Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder.CNS Spectr. 2017 Feb;22(1):31-40. doi: 10.1017/S1092852916000353. Epub 2016 Aug 18.
280 STX1A gene variations contribute to the susceptibility of children attention-deficit/hyperactivity disorder: a case-control association study.Eur Arch Psychiatry Clin Neurosci. 2019 Sep;269(6):689-699. doi: 10.1007/s00406-019-01010-3. Epub 2019 Apr 11.
281 Girls' attentive traits associate with cerebellar to dorsal attention and default mode network connectivity.Neuropsychologia. 2019 Apr;127:84-92. doi: 10.1016/j.neuropsychologia.2019.02.011. Epub 2019 Feb 20.
282 Evaluation of common variants in 16 genes involved in the regulation of neurotransmitter release in ADHD.Eur Neuropsychopharmacol. 2013 Jun;23(6):426-35. doi: 10.1016/j.euroneuro.2012.07.014. Epub 2012 Aug 30.
283 Discovery of Biomarker Panels for Neural Dysfunction in Inborn Errors of Amino Acid Metabolism.Sci Rep. 2019 Jun 24;9(1):9128. doi: 10.1038/s41598-019-45674-2.
284 In Vitro Neurochemical Assessment of Methylphenidate and Its "Legal High" Analogs 3,4-CTMP and Ethylphenidate in Rat Nucleus Accumbens and Bed Nucleus of the Stria Terminalis.Front Psychiatry. 2018 May 28;9:149. doi: 10.3389/fpsyt.2018.00149. eCollection 2018.
285 Overexpression of the Thyroid Hormone-Responsive (THRSP) Gene in the Striatum Leads to the Development of Inattentive-like Phenotype in Mice.Neuroscience. 2018 Oct 15;390:141-150. doi: 10.1016/j.neuroscience.2018.08.008. Epub 2018 Aug 21.
286 Executive Function Training for Children with Attention Deficit Hyperactivity Disorder.Chin Med J (Engl). 2017 Mar 5;130(5):549-558. doi: 10.4103/0366-6999.200541.
287 Does Anxiety Enhance or Hinder Attentional and Impulse Control in Youth With ADHD? An ERP Analysis.J Atten Disord. 2020 Oct;24(12):1746-1756. doi: 10.1177/1087054717707297. Epub 2017 May 11.
288 The ATXN1 and TRIM31 genes are related to intelligence in an ADHD background: evidence from a large collaborative study totaling 4,963 subjects.Am J Med Genet B Neuropsychiatr Genet. 2011 Mar;156(2):145-57. doi: 10.1002/ajmg.b.31149. Epub 2010 Dec 16.
289 Sex-specific influence of DRD2 on ADHD-type temperament in a large population-based birth cohort.Psychiatr Genet. 2012 Aug;22(4):197-201. doi: 10.1097/YPG.0b013e32834c0cc8.
290 Further replication of the synergistic interaction between LPHN3 and the NTAD gene cluster on ADHD and its clinical course throughout adulthood.Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):120-127. doi: 10.1016/j.pnpbp.2017.06.011. Epub 2017 Jun 15.
291 Relationship between ADHD and anxiety in boys: results from a family study.J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):988-96. doi: 10.1097/00004583-199608000-00009.
292 Function and regulation of AUTS2, a gene implicated in autism and human evolution.PLoS Genet. 2013;9(1):e1003221. doi: 10.1371/journal.pgen.1003221. Epub 2013 Jan 17.
293 Cognitive and behavioral precursors of schizophrenia.Dev Psychopathol. 1999 Summer;11(3):487-508. doi: 10.1017/s0954579499002175.
294 Genome-wide association study of inattention and hyperactivity-impulsivity measured as quantitative traits.Twin Res Hum Genet. 2013 Apr;16(2):560-74. doi: 10.1017/thg.2013.12.
295 Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.Clin Pharmacol Ther. 2003 Mar;73(3):178-91. doi: 10.1067/mcp.2003.25.
296 Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype.J Med Genet. 2003 Oct;40(10):733-40. doi: 10.1136/jmg.40.10.733.
297 The dopaminergic system in attention deficit/hyperactivity disorder.Congenit Anom (Kyoto). 2003 Jun;43(2):114-22. doi: 10.1111/j.1741-4520.2003.tb01035.x.
298 The FMR1 premutation and attention-deficit hyperactivity disorder (ADHD): evidence for a complex inheritance.Behav Genet. 2012 May;42(3):415-22. doi: 10.1007/s10519-011-9520-z. Epub 2011 Nov 19.
299 Association between GABA3 Gene Polymorphisms and Attention Deficit Hyperactivity Disorder in Korean Children.Psychiatry Investig. 2017 Sep;14(5):693-697. doi: 10.4306/pi.2017.14.5.693. Epub 2017 Sep 11.
300 Xp11.2 microduplications including IQSEC2, TSPYL2 and KDM5C genes in patients with neurodevelopmental disorders.Eur J Hum Genet. 2016 Mar;24(3):373-80. doi: 10.1038/ejhg.2015.123. Epub 2015 Jun 10.
301 DNA variants in the human RAB3A gene are not associated with autism.Genes Brain Behav. 2004 Apr;3(2):123-4. doi: 10.1111/j.1601-183x.2003.00058.x.
302 Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223.
303 SLITRK1 binds 14-3-3 and regulates neurite outgrowth in a phosphorylation-dependent manner.Biol Psychiatry. 2009 Nov 15;66(10):918-25. doi: 10.1016/j.biopsych.2009.05.033. Epub 2009 Jul 29.
304 The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate.Eur Neuropsychopharmacol. 2005 Jan;15(1):95-101. doi: 10.1016/j.euroneuro.2004.06.004.